Wang Zhuo, Yang Guozi, Zhang Yu-Yu, Yao Yan, Dong Li-Hua
Department of Radiotherapy, Norman Bethune First Hospital Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Medicine (Baltimore). 2017 Nov;96(44):e8444. doi: 10.1097/MD.0000000000008444.
The prognosis of glioblastoma (GBM), a major subtype of grade IV glioma, is rather poor nowadays. The efficiency of chemotherapy serving as the adjunct to radiotherapy (RT) for treating GBM is still controversial. In this study, we aim to investigate the overall survival (OS) and progression-free survival (PFS) in patients with newly diagnosed GBM received RT plus chemotherapy or with RT alone.Literatures were searched from the PubMed, Embase, and Cochrane Library between January 2001 and June 2015. Study selection was conducted based on the following criteria: randomized clinical trial (RCT) of adjuvant RT plus chemotherapy versus RT alone; studies comparing OS and/or PFS; and studies including cases medically confirmed of newly diagnosed GBM.Five RCTs (1655 patients) were eligible in this study. The meta-analysis showed a significant improvement in OS of patients treated with RT plus oral chemotherapy compared with that of RT alone (hazard ratio 0.70; 95% confidence interval, 0.56-0.88, P = .002).Adjuvant chemotherapy confers a survival benefit in patients newly diagnosed with GBM.
胶质母细胞瘤（GBM）是IV级胶质瘤的主要亚型，目前其预后相当差。化疗作为放疗（RT）治疗GBM的辅助手段，其疗效仍存在争议。在本研究中，我们旨在调查新诊断的GBM患者接受放疗加化疗或单纯放疗后的总生存期（OS）和无进展生存期（PFS）。
检索了2001年1月至2015年6月期间PubMed、Embase和Cochrane图书馆的文献。研究选择基于以下标准：辅助放疗加化疗与单纯放疗的随机临床试验（RCT）；比较OS和/或PFS的研究；以及包括经医学确诊的新诊断GBM病例的研究。
本研究纳入了5项RCT（1655例患者）。荟萃分析显示，与单纯放疗相比，接受放疗加口服化疗的患者OS有显著改善（风险比0.70；95%置信区间，0.56 - 0.88，P = 0.002）。
辅助化疗对新诊断的GBM患者有生存益处。
